CPX-351 (cytarabine liposomale et daunorubicine) versus vénétoclax associé à un agent hypométhylant dans la leucémie myéloïde aiguë nouvellement diagnostiquée : une étude rétrospective portant sur 600 patients de la Mayo Clinic | Blood Cancer Journal – Nature
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving…
Contenu integral de l article
The comparative value of liposomal cytarabine/daunorubicin (CPX-351) versus venetoclax plus a hypomethylating agent (Ven-HMA) in the frontline treatment of older adults with primary (de novo) or secondary acute myeloid leukemia (AML) remains uncertain. In the current study, we retrospectively examined outcomes of 600 patients with newly diagnosed AML treated with CPX-351 (N = 112) or Ven-HMA (N = 488). AML subtypes included de novo (N = 277,46%), post-myelodysplastic syndrome (post-MDS, N = 114,19%), post-myeloproliferative neoplasm (post-MPN, N = 70,12%), post-MDS/MPN (N = 36,6%), and t-AML (N = 103,17%). Patients receiving CPX-351 were younger (median 65 vs. 73 years; p
Produits lies a cet article
Ces produits ont ete automatiquement associes au titre, au resume et au contenu de l article.
Questions frequentes
Which products are related to this article?
The system matched these relevant products from the article content: Lucius Venetoclax – Acheter en ligne VECLADX Venetoclax 100 mg.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.